Our results with BM-MSCs together with the results ofKuci et al. with CIK cells1 emphasize that cell mediateddelivery of TRAIL to metastatic RMS tumor sites can bea useful approach in RMS therapy. Targeted delivery ofTRAIL to tumors may allow systemic exposure ofpatients to drugs (e.g. the proteasome inhibitor bortezomib)that may overcome resistance for TRAIL-inducedapoptosis in RMS cells.
Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro / Barti-Juhasz, H.; Mihalik, R.; Nagy, K.; Grisendi, G.; Dominici, M.; Petak, I.. - In: HAEMATOLOGICA. - ISSN 0390-6078. - ELETTRONICO. - 96:3(2011), pp. 21-22. [10.3324/haematol.2010.036822]
Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro
Grisendi G.;Dominici M.;
2011
Abstract
Our results with BM-MSCs together with the results ofKuci et al. with CIK cells1 emphasize that cell mediateddelivery of TRAIL to metastatic RMS tumor sites can bea useful approach in RMS therapy. Targeted delivery ofTRAIL to tumors may allow systemic exposure ofpatients to drugs (e.g. the proteasome inhibitor bortezomib)that may overcome resistance for TRAIL-inducedapoptosis in RMS cells.
| File | Dimensione | Formato | |
|---|---|---|---|
|
5921-Article Text-29751-1-10-20200723.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
2.09 MB
Formato
Adobe PDF
|
2.09 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
